Current stock page

Financial Data

DFTX Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

DFTXDefinium Therapeutics, Inc.

Healthcare / Biotechnology

Relative Leader / Watch

Sector Leader

NeutralEdge 10/10
$32.08−$0.92 (−2.79%)

Latest quote

  • Momentum
    64
  • Value
    —
  • Quality
    60
  • Risk resilience
    44
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$0$0$0$0$0$0$0$0
Gross Profit$0$0$0$0$0$0$0$0
Operating Income-$72.28M-$75.08M-$59.22M-$47.58M-$45.67M-$40.9M-$32.16M-$32.46M
Net Income-$50.96M-$158.99M-$77.1M-$50.44M-$67.27M-$42.74M-$23.35M-$34.74M
EPS-$0.37-$1.44-$0.71-$0.51-$0.78-$0.5-$0.27-$0.41
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$52.98M-$52.78M-$42.63M-$41.89M-$29.57M-$29.6M-$29.42M-$25.35M
Capital Expenditure$0$0$0$0$0$0$0$0
Free Cash Flow-$52.98M-$52.78M-$42.63M-$41.89M-$29.57M-$29.6M-$29.42M-$25.35M
Net Cash Provided By Operating Activities-$52.98M-$52.78M-$42.63M-$41.89M-$29.57M-$29.6M-$29.42M-$25.35M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$1.07B$1.11B$401.29M$440.1M$236.92M$265.09M$275.32M$302.15M
Total Debt$36.66M$36.47M$0$0$40.39M$41.19M$22.04M$21.85M
Cash And Cash Equivalents$241.15M$655.27M$262.52M$257.84M$19.96M$33.39M$82.85M$273.74M
Total Liabilities$106.25M$194.22M$122.44M$107.77M$106.32M$79.69M$52.52M$60.7M
Total Stockholders Equity$968.03M$918.68M$278.85M$332.33M$130.6M$185.4M$222.81M$241.45M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio5.025.569.054.657.464.182.532.3
P/S ratio————————
Debt To Equity0.040.04000.310.220.10.09
Free Cash Flow Yield-3.91%-3.27%-5.69%-8.45%-11.70%-13.09%-16.34%-14.26%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio5.025.569.054.657.464.182.532.3
P/S ratio————————
Return On Equity-34.86%-38.51%-85.19%-55.30%-128.72%-61.77%-34.84%-45.01%
Debt To Equity0.040.04000.310.220.10.09

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-10.59x
Pb4.51x
EPS Growth Yoy52.56%
Gross Margin0.00%
Operating Margin0.00%
ROE-54.04%
ROIC-25.25%
Debt To Equity0.04
FCF Yield-4.33%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$32.08
Volume778,188
RSI (14)41.55
MACD-0.89
MACD signal-0.82
MACD histogram-0.07
ADX (14)15
SMA (50)$36.07
SMA (200)$30.43
ATR (14)$2.04
Historical volatility (annualized)75.90%
Volume (20-day average)1.64M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score44/100
Beta1.14
Annual volatility77.71%
Max Drawdown-37.34%
Sharpe Ratio1.61
VaR (95%, 1-day)-5.36%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

DFTX Financial Data FAQ

What is Definium Therapeutics, Inc.'s revenue?

Definium Therapeutics, Inc.'s revenue is one of the core financial data points for DFTX. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Definium Therapeutics, Inc.'s revenue growing?

Revenue growth shows whether Definium Therapeutics, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is DFTX's EPS?

DFTX's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Definium Therapeutics, Inc.'s net income?

Definium Therapeutics, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Definium Therapeutics, Inc. generate?

Free cash flow shows how much cash Definium Therapeutics, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Definium Therapeutics, Inc. have?

Cash and debt help frame DFTX's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.